

Contents lists available at ScienceDirect

# Journal of Fluorine Chemistry



journal homepage: www.elsevier.com/locate/fluor

# Asymmetric Michael addition of $\alpha$ -fluoro- $\alpha$ -phenylsulfonyl ketones to nitroolefins catalyzed by phenylalanine-based bifunctional thioureas<sup>\*</sup>

## Hai-Feng Cui, Peng Li, Xiao-Wei Wang, Shi-Zheng Zhu, Gang Zhao\*

Key Laboratory of Synthetic Chemistry of Natural Substances and Key Laboratory of Organofluorine Chemistry, Shanghai Institute of Organic Chemistry, 345 Lingling Road, Shanghai 200032, China

#### ARTICLE INFO

#### ABSTRACT

Article history: Received 26 April 2011 Received in revised form 19 May 2011 Accepted 30 May 2011 Available online 18 July 2011

#### *Keywords:* Thiourea Fluorine-containing Enantioselectivities Chiral fluorinated compounds

#### 1. Introduction

Nowadays, the great importance of fluorine-containing compounds has been well recognized in kinds of fields such as material, medicinal, pharmaceutical and agrochemical science [1]. The introduction of the fluorine atom has almost become one of the routine practices in the studies of these sciences. Therefore, there has been a great demand for the development of more selective, safe and mild fluorination methods [2]. With the rapid development of organocatalysis over the past decade, the organocatalytic asymmetric synthesis of fluorinated molecules has received considerable attentions among organic chemists and impressive advancement has been achieved [3]. Particularly, the asymmetric addition reaction of fluorine-substituted monofluorinated nucleophiles to various electrophiles, with the concomitant formation of a new C-C bond and the construction of a chiral fluorinated center, has been one of the research focuses. For examples,  $\alpha$ -fluoro- $\beta$ keto esters have been used as nucleophiles in asymmetric Michael additions with nitroolefins, N-alkyl maleimides and Mannich reactions [4]. Our group has also reported the asymmetric Robinson annulation between  $\alpha$ -fluoro- $\beta$ -keto esters and  $\alpha$ , $\beta$ unsaturated ketones catalyzed by primary-secondary diamines to synthesize multiply substituted fluorinated chiral cyclohexenones

Phenylalanine-based bifunctional thiourea derivatives promoted the asymmetric Michael addition of  $\alpha$ -fluoro- $\alpha$ -phenylsulfonyl ketones to nitroolefins, affording enantiomerically enriched fluorine-containing multifunctional molecules containing adjoining chiral fluorine-substituted quaternary and tertiary centers in good yields and enantioselectivities.

© 2011 Elsevier B.V. All rights reserved.

with a fluorinated quaternary chiral center in excellent enantioselectivities [5].

Besides  $\alpha$ -fluoro- $\beta$ -keto esters, the use of  $\alpha$ -nitro, cyano, ester, or acetyl-substituted fluoro(phenylsulfonyl)methanes as the nucleophile has been particularly intriguing due to their convertibility into a variety of functionalized monofluoromethylated compounds, which are crucial synthons for many valuable compounds in the pharmaceutical arena [4i-j,6]. Prakash et al. have achieved enantioselective and diastereoselective Michael additions of these fluorine containing (phenylsulfonyl)methane derivatives to chalcones using cinchona alkaloids-based bifunctional catalysts [4j,k]. In addition, their organocatalytic asymmetric Michael additions to  $\alpha$ ,  $\beta$ -unsaturated aldehydes have also been reported by Palomo [4h] and Córdova [4i]. Surprisingly, to the best of our knowledge, there has been no report on the organocatalyzed Michael addition of  $\alpha$ -fluoro- $\alpha$ -phenylsulfonyl ketones to nitroolefins. Together with the rich chemistry of the nitro group [7], the multiply functionalized product of such an addition could have great potential in organic synthesis and related areas. Herein, we report our results on this kind of reaction using amino acid and cinchona alkaloid-derived bifunctional thiourea catalysts (Fig. 1).

#### 2. Results and discussion

Initially, cinchona alkaloid based bifunctional catalyst **1**, the optimum catalyst in Prakash's study [4j], was examined in the model reaction of 2-fluoro-1-phenyl-2-(phenylsulfonyl)ethanone **3a** to (E)-(2-nitrovinyl)benzene **4a** in xylene at room temperature.

<sup>\*</sup> Dedicated to Professor Wei-Yuan Huang on the occasion of his 90th birthday.

<sup>\*</sup> Corresponding author. Tel.: +86 21 54925182; fax: +86 21 64166128. *E-mail address:* zhaog@mail.sioc.ac.cn (G. Zhao).

<sup>0022-1139/\$ –</sup> see front matter @ 2011 Elsevier B.V. All rights reserved. doi:10.1016/j.jfluchem.2011.05.029



Fig. 1. Structures of the catalysts studied.

Although a good vield and excellent diastereoselectivity were gained, the enantioselectivity was not satisfactory (Table 1, entry 1). Based on our recent efforts on the development of organocatalysts from easily available chiral amino acids, several other thiourea catalysts 2a-2k were synthesized and examined [7]. Variation in the chiral amino acid skeletons revealed that phenylalanine-derived catalyst 2a is slightly better than phenylglycine-derived **2b** and isoleucine-derived **2c**, in terms of enantioselectivity (Table 1, entries 2-4). While changing the substituents on the benzene ring of the group (thiourea moiety) to electron-donating and bulky ones could lead to much improved enantioselectivities, the yields decreased dramatically (Table 1, entries 4-8). Pleasingly, further structural optimization by increasing the steric hindrance of tertiary amine moiety gave rise to the best catalyst **2k**, providing the desired product **5a** in high enantioselectivity and with good yield and excellent diastereoselectivity (Table 1, entry 12). Notably, all the catalysts with different structures gave the same excellent d.r. value of 20:1.

Next, different solvents were tested with the optimal catalyst 2k (Table 2). In spite that the reaction performed in carbon tetrachloride proceeded faster and gave higher yields, a slight drop in the enantioselectivity was observed (Table 2, entries 3). In contrast, more polar chlorine-containing solvents dichloromethane, chloroform or MTBE gave extremely low yields being the lower conversion of reactants (Table 2, entries 4-6). While the use of toluene or a co-solvent of carbon tetrachloride and xylenes failed to provide better results, the use of pure *m*-xylene led to somewhat improved overall results (Table 2, entries 7-8).

#### Table 1

Screening of catalysts <sup>a</sup> .Ph <sup>^</sup>	O SO <sub>2</sub> Ph + F 3a	Ph NO <sub>2</sub> Cat. (20 mol%) Xylenes, rt. Ph	Ph NO <sub>2</sub> 'SO <sub>2</sub> Ph 5a	
Entry	Cat.	Yield of <b>5a</b> /% <sup>b</sup>	$dr.  ext{ of } \mathbf{5a}^{c}$	<i>ee</i> . of <b>5a</b> /% <sup>d</sup>
1	1	85	20:1	70
2	2a	80	20:1	55
3	2b	75	20:1	60
4	2c	90	20:1	64
5	2d	70	20:1	68
6	2e	30	20:1	82
7	2f	33	20:1	89
8	2g	66	20:1	60
9	2h	95	20:1	73
10	2i	90	20:1	68
11	2j	95	20:1	75
12	2k	75	20:1	93

Unless otherwise noted, the reaction was carried out with 3a (0.1 mmol), 4a (0.15 mmol), catalyst (20 mol%) and solvent (0.5 mL) at room temperature for 3 days. b Isolated yield.

с

Determined by <sup>19</sup>F NMR.

Determined by HPLC.

### Table 2



<sup>a</sup> Unless otherwise noted, the reaction was carried out with **3a** (0.1 mmol), **4a** (0.15 mmol), catalyst (20 mol%) and solvent (0.5 mL) at room temperature.

<sup>b</sup> Isolated yield.

<sup>c</sup> Determined by <sup>19</sup>F NMR.

<sup>d</sup> Determined by HPLC.

#### Table 3

Study on the re-	action scope with different 3	$3 \text{ and } 4^{a} \cdot \mathbb{R}^{1} \xrightarrow{O} SO_{2} Ph + F $	R <sup>2</sup> NO <sub>2</sub> <u>2k (20</u> <i>m</i> -Xy)	Dene, rt. R <sup>1</sup> F S	$NO_2$ $O_2Ph$	
Entry	R <sup>1</sup>	R <sup>2</sup>	Time/h	Yield/% <sup>b</sup>	dr. <sup>c</sup>	ee./% <sup>d</sup>
1	$C_6H_5$ , ( <b>3a</b> )	$C_6H_5$ , ( <b>4a</b> )	72	80( <b>5a</b> )	20:1	94
2	CH <sub>3</sub> , ( <b>3b</b> )	$C_6H_5$ , ( <b>4a</b> )	72	90( <b>5b</b> )	6:1	96
3	$C_{6}H_{5}$ , ( <b>3a</b> )	$p-FC_{6}H_{4}$ , ( <b>4b</b> )	72	88( <b>5</b> c)	14:1	89
4	$C_6H_5$ , ( <b>3a</b> )	p-BrC <sub>6</sub> H <sub>4</sub> , ( <b>4c</b> )	48	90( <b>5d</b> )	17:1	90
5	$C_6H_5$ , ( <b>3a</b> )	$p-CH_{3}C_{6}H_{4}$ , ( <b>4d</b> )	72	85( <b>5e</b> )	20:1	90
6	$C_6H_5$ , ( <b>3a</b> )	$p-CH_{3}OC_{6}H_{4}$ , ( <b>4e</b> )	72	82( <b>5f</b> )	10:1	93
7	$C_6H_5$ , ( <b>3a</b> )	$p-PhC_{6}H_{4}, (4f)$	72	89( <b>5g</b> )	20:1	90
8	$C_6H_5$ , ( <b>3a</b> )	$p-NO_2C_6H_4$ , ( <b>4g</b> )	72	70( <b>5h</b> )	14:1	91
9	$C_6H_5$ , ( <b>3a</b> )	o-BrC <sub>6</sub> H <sub>4</sub> , ( <b>4h</b> )	72	90( <b>5i</b> )	15:1	87
10	$C_6H_5$ , ( <b>3a</b> )	m-BrC <sub>6</sub> H <sub>4</sub> , ( <b>4i</b> )	72	85( <b>5j</b> )	15:1	86
11	$C_6H_5$ , ( <b>3a</b> )	1-Naphthyl, ( <b>4j</b> )	72	85( <b>5k</b> )	20:1	92
12	$C_6H_5$ , ( <b>3a</b> )	2-Furyl, ( <b>4</b> k)	72	93( <b>5I</b> )	20:1	91
13	$C_6H_5$ , ( <b>3a</b> )	2-Thienyl, ( <b>4</b> I)	72	82( <b>5m</b> )	16:1	91
14	$C_6H_5$ , ( <b>3a</b> )	<i>n</i> -Bu, ( <b>4m</b> )	72	90( <b>5n</b> )	5:1	90
15	C <sub>6</sub> H <sub>5</sub> , ( <b>3a</b> )	<i>i</i> -Pr, ( <b>4n</b> )	72	70(50)	20:1	91

<sup>a</sup> Unless otherwise noted, the reaction was carried out with 3 (0.3 mmol), 4 (0.45 mmol), catalyst (20 mol%) and solvent (3.0 mL) at room temperature.

<sup>b</sup> Isolated yield.

<sup>c</sup> Determined by <sup>19</sup>F NMR.

<sup>d</sup> Determined by HPLC.

Interestingly, the *dr*. value in all these cases examined also remained excellent without negligible changes.

With the optimized reaction conditions in hand, a selected spectrum of different substrates was examined to test the scope of this reaction (Table 3). Alkyl ketone derivative **3b** ( $R^1 = CH_3$ ) also participated in the reaction well to give the adduct **5b** in excellent yield and enantioselectivity, albeit with a diminished diastereoselectivity of 6:1 (Table 3, entry 2). With regard to different olefins 4, when R<sup>2</sup> was an aryl group, substrates with electron-donating/ withdrawing substituents on the benzene ring were generally well tolerated, though slight drops in dr. and ee. values were observed (Table 3, entries 3–11). Heterocyclic substrates 4k and 4l also gave comparably good results (Table 3, entries 12–13). Notably, alkyl substituted nitroolefins also proved to be highly applicable to the reaction system: the bulkier 4n (R<sup>2</sup> = *i*-Pr) was much more favored over  $4m(R^2 = n-Bu)$  in terms of dr. value while both gave excellent ee. values (Table 3, entries 14-15). It is also worth mentioning that the excellent diastereoselectivities obtained in most cases in our system poses a sharp contrast to Lu's work [4c] dealing with the addition of  $\alpha$ -fluoro- $\beta$ -keto esters to nitroolefins, where only modest *dr*. values (no more than 6:1) were obtained in most cases. The absolute configuration of the major isomer of **5d** was determined by X-ray crystallographic analysis (Fig. 2), and the others were assigned by analogy assuming a similar mechanism was followed [8]. A possible transition state model was proposed to explain the stereochemical results of the Michael addition. Thus,



Fig. 2. ORTEP structure of compound 5d.



Scheme 1. Proposed transition-state structure.



Scheme 2. Conversion of 5a to 6.

the bifunctional chiral thiourea catalyst activated the nitroolefin through H-bonding. The  $\alpha$ -fluoro- $\alpha$ -phenylsulfonyl ketone attacked the nitroolefin from the *Si* face leading the Michael product of the 2*S*, 3*S* configuration (Scheme 1).

Nitrones have attracted growing interests among synthetic chemists due to their successful applications as building blocks in the synthesis of various natural and biologically active compounds [9,10]. As an illustration of the utility of the present reaction, the Michael adduct **5a** was transformed to pyrrolidine-type nitrone product **6** via a single simple hydrogenation step. The densely functionalized cyclic nitrone **6** was obtained in good yield, and with no decrease in *dr.* and *ee.* values (Scheme 2).

#### 3. Conclusion

In summary, we have reported the organocatalyzed asymmetric Michael addition of  $\alpha$ -fluoro- $\alpha$ -phenylsulfonyl ketones to nitroolefins to afford enantiomerically enriched fluorine-containing multifunctional molecules containing adjoining fluorine-substituted quaternary and tertiary centers. Using readily available phenylalanine-based bifunctional thiourea derivatives as the catalysts, the desired products were obtained with good to excellent yield and stereoselectivity.

#### 4. Experimental

Unless otherwise indicated, chemicals and solvents were purchased from commercial suppliers and purified by standard techniques. The <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a DPX-300 or Varian EM-360 (300 MHz) and DPX-400 (100 MHz) with TMS as the internal standard. <sup>19</sup>F NMR spectra were recorded at 282 MHz with CFCl<sub>3</sub> as the external standard. Analytical highperformance liquid chromatography (HPLC) was carried out on WATERS equipment using a chiral column. Melting points were determined on a SGW X-4 apparatus, and are uncorrected. Optical rotations were measured on a JASCO P-1030 Polarimeter at  $\lambda$  = 589 nm. IR spectra were recorded on a NicoletbAV-360 instrument. Elementary analysis was taken on a Vario EL III elementary analysis instrument. LRMS and HRMS analyses were performed on API 200 LC/MS system (Applied Biosystems Co. Ltd.) or APEXIII(7.0 T) FTMS mass spectrometer, respectively.

#### 4.1. General procedure for the Michael addition catalyzed by 2k

The solution of 2k (6 mg, 0.01 mmol), 3a (14 mg, 0.05 mmol) and 4a (10 mg, 0.07 mmol) in *m*-xylene (0.5 mL) was stirred at room temperature and monitored by TLC. After completion (72 h), the mixture was purified by flash chromatography (dichloromathane/petro ether: 1/1) to provide white solid product 5a 17 mg, in 80% yield.

4.1.1. 2-Fluoro-4-nitro-1,3-diphenyl-2-(phenylsulfonyl)butan-1-one 5a

White solid; Mp: 90–92 °C;  $[\alpha]_D^{25} = 45.1$  (c = 1.34 in CHCl<sub>3</sub>); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.83–7.77 (m, 2H), 7.66–7.56 (m, 1H), 7.51–7.37 (m, 3H), 7.34–7.10 (m, 9H), 5.69–5.56 (m, 1H), 5.30–5.17 (m, 1H), 4.74–4.64 (m, 1H); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>)  $\delta$  –145.72 (d, J = 17.3 Hz, 1F); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  193.7 (d, J = 25.2 Hz), 135.3, 135. 2, 134.3, 134.0, 131.6, 130.7, 129.7, 129.5, 129.5, 129.3, 129.1, 110.5 (d, J = 240.9 Hz), 75.3 (d, J = 5.2 Hz), 47.4 (d, J = 22.2 Hz); IR (KBr)  $\nu$  2933, 1675, 1560, 1453, 1331, 1158 cm<sup>-1</sup>; ESI-MS (m/z): 450.0 (M + 23)<sup>+</sup>; HRMS (EI): m/z: calcd. for C<sub>22</sub>H<sub>18</sub>NO<sub>5</sub>FS: 427.0890; found: 427.0892 [M]<sup>+</sup>; HPLC separation conditions: Chiralcel ADH, 20 °C, 254 nm, 4:1 hexane:*i*-PrOH, 0.8 mL/min;  $t_R = 32.0$  min (minor enantiomer), 37.8 min (major enantiomer).

4.1.2. 3-Fluoro-5-nitro-4-phenyl-3-(phenylsulfonyl)pentan-2-one 5b White solid; Mp: 115–116 °C;  $[\alpha]_D^{27} = 93.4$  (c = 1.03 in CHCl<sub>3</sub>); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.89–7.72 (m, 3H), 7.63–7.54 (m, 2H), 7.34–7.19 (m, 3H), 7.16–7.04 (m, 2H), 5.50–5.42 (m, 1H), 5.23–5.06 (m, 1H), 4.57–4.37 (m, 1H), 1.87 (d, J = 5.9 Hz, 3H); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>)  $\delta$  –148.42 (d, J = 8.0 Hz, 1F); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  201.5 (d, J = 27.7 Hz), 135.5, 134.2, 131.4, 130.5, 129.6, 129.4, 129.2, 129.1, 107.6 (d, J = 236.4 Hz), 74.9 (d, J = 5.9 Hz), 46.2 (d, J = 22.5 Hz), 28.7; IR (KBr)  $\nu$  3066, 1728, 1560, 1497, 1449, 1332, 1160 cm<sup>-1</sup>; ESI-MS (m/z): 388.1 (M + 23)<sup>+</sup>; HRMS (EI): m/z: calcd. for C<sub>17</sub>H<sub>16</sub>NO<sub>5</sub>FS: 365.0733; found: 365.0738 [M]<sup>+</sup>; HPLC separation conditions: Chiralcel ODH, 20 °C, 254 nm, 4:1 hexane:*i*-PrOH, 0.7 mL/min;  $t_R = 17.9$  min (minor enantiomer), 19.1 min (major enantiomer).

#### 4.1.3. 2-Fluoro-3-(4-fluorophenyl)-4-nitro-1-phenyl-2-(phenylsulfonyl)butan-1-one 5c

Colorless oil;  $[\alpha]_D^{25} = 36.6$  (*c* = 1.28 in CHCl<sub>3</sub>); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.76 (d, *J* = 7.2 Hz, 2H), 7.62 (t, *J* = 7.0 Hz, 1H), 7.53–7.34 (m, 5H), 7.30–7.11 (m, 4H), 6.91 (t, *J* = 8.8 Hz, 2H), 5.60–5.46 (m, 1H), 5.27–5.07 (m, 1H), 4.80–4.65 (m, 1H); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>)  $\delta$  –111.67 (s, 1F), –147.57 (d, *J* = 20.5 Hz, 1F); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  193.3 (d, *J* = 24.2 Hz), 163.1 (d, *J* = 249.4 Hz), 135.3, 135.1 (d, *J* = 4.4 Hz), 134.3, 131.6 (d, *J* = 8.8 Hz), 130.6, 129.6, 129.5, 129.3, 128.3, 127.4 (d, *J* = 2.8 Hz), 116.1 (d, *J* = 21.4 Hz), 110.3 (d, *J* = 241.2 Hz), 75.4 (d, *J* = 5.3 Hz), 46.7 (d, *J* = 22.6 Hz); IR (film)  $\nu$  3065, 1677, 1597, 1561, 1511, 1448, 1336, 1161 cm<sup>-1</sup>; ESI-MS (*m*/*z*): 468.0 (M + 23)<sup>+</sup>; HRMS (EI): *m*/*z*: calcd. for  $C_{22}H_{17}NO_5F_2S$ : 445.0796; found: 445.0788 [M]<sup>+</sup>; HPLC separation conditions: Chiralcel ADH, 20 °C, 254 nm, 4:1 hexane:*i*-PrOH, 0.7 mL/min; *t*<sub>R</sub> = 32.5 min (minor enantiomer), 45.3 min (major enantiomer).

#### 4.1.4. 2-Fluoro-3-(4-bromophenyl)-4-nitro-1-phenyl-2-(phenylsulfonyl)butan-1-one 5d

White solid; Mp: 130–132 °C;  $[\alpha]_D^{23} = 27.5$  (*c* = 1.20 in CHCl<sub>3</sub>); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.74 (d, *J* = 7.6 Hz, 2H), 7.62 (t, *J* = 7.3 Hz, 1H), 7.54–7.18 (m, 9H), 7.07 (d, *J* = 8.4 Hz, 2H), 5.56–5.39 (m, 1H), 5.22–5.07 (m, 1H), 4.82–4.61 (m, 1H); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>)  $\delta$  –147.57 (d, *J* = 20.5 Hz, 1F); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ 193.0 (d, *J* = 24.0 Hz), 135.3, 135.0 (d, *J* = 4.2 Hz), 134.4, 134.3, 132.2, 131.4, 130.8, 130.6, 129.6 (d, *J* = 8.8 Hz), 129.3, 128.4, 123.7, 110.4 (d, *J* = 241.6 Hz), 75.2 (d, *J* = 4.8 Hz), 47.0 (d, *J* = 22.1 Hz); IR (KBr)  $\nu$  2924, 1677, 1595, 1561, 1448, 1338, 1161 cm<sup>-1</sup>; ESI-MS (*m*/*z*): 528.1 (M + 23)<sup>+</sup>; HRMS (EI): *m*/*z*: calcd. for C<sub>22</sub>H<sub>17</sub>NO<sub>5</sub>FSBr: 504.9995; found: 504.9996 [M]<sup>+</sup>; HPLC separation conditions: Chiralcel ADH, 20 °C, 254 nm, 4:1 hexane:*i*-PrOH, 0.9 mL/min; *t*<sub>R</sub> = 48.9 min (minor enantiomer), 84.8 min (major enantiomer).

#### 4.1.5. 2-Fluoro-4-nitro-1-phenyl-2-(phenylsulfonyl)-3-p-tolylbutan-1-one **5e**

Colorless oil;  $[\alpha]_D^{27} = 43.9$  (c = 1.38 in CHCl<sub>3</sub>); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.78 (d, J = 7.7 Hz, 2H), 7.61 (t, J = 6.9 Hz, 1H), 7.52–7.30 (m, 5H), 7.29–7.15 (m, 2H), 7.11–6.91 (m, 4H), 5.67–5.49 (m, 1H), 5.28–5.10 (m, 1H), 4.74–4.55 (m, 1H); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>)  $\delta$  –146.23 (d, J = 11.5 Hz, 1F); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  193.6 (d, J = 24.4 Hz), 139.2, 135.3 (d, J = 24.4 Hz), 135.2, 134.4, 134.0, 130.7, 129.8, 129.7, 129.6, 129.5, 129.2, 128.5, 128.2, 110.2 (d, J = 240.6 Hz), 75.5 (d, J = 5.1 Hz), 47.1 (d, J = 22.5 Hz), 21.1; IR (film)  $\nu$  2924, 1677, 1596, 1558, 1448, 1159 cm<sup>-1</sup>; ESI-MS (m/z): 464.1 (M + 23)<sup>+</sup>; HRMS (EI): m/z: calcd. for C<sub>23</sub>H<sub>20</sub>NO<sub>5</sub>FS: 441.1046; found: 441.1042 [M]<sup>+</sup>; HPLC separation conditions: Chiralcel ADH, 20 °C, 254 nm, 4:1 hexane:*i*-PrOH, 0.6 mL/min;  $t_R = 26.2$  min (minor enantiomer), 44.1 min (major enantiomer).

#### 4.1.6. 2-Fluoro-3-(4-methoxyphenyl)-4-nitro-1-phenyl-2-(phenylsulfonyl)butan-1-one 5f

White solid; Mp: 84–85 °C,  $[\alpha]_D^{25} = 42.5$  (c = 1.20 in CHCl<sub>3</sub>); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.78 (d, J = 8.1 Hz, 2H), 7.62 (t, J = 7.2 Hz, 1H), 7.48–7.33 (m, 5H), 7.23–7.21 (m, 2H), 7.08 (d, J = 7.7 Hz, 2H), 6.73 (d, J = 8.7 Hz, 2H), 5.59–5.50 (m, 1H), 5.25–5.10 (m, 1H), 4.74–4.53 (m, 1H); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>)  $\delta$  –146.39 (d, J = 17.3 Hz, 1F); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  193.6 (d, J = 24.2 Hz), 160.2, 135.2, 134.5, 134.0, 130.9, 130.6, 129.6, 129.5, 129.2, 128.2, 123.2, 114.4, 110.3 (d, J = 240.0 Hz), 75.5 (d, J = 4.4 Hz), 55.24, 46.7 (d, J = 22.5 Hz); IR (KBr)  $\nu$  2926, 1677, 1611, 1557, 1448, 1255 cm<sup>-1</sup>; ESI-MS (m/z): 480.1 (M+23)<sup>+</sup>; HRMS (EI): m/z: calcd. for C<sub>23</sub>H<sub>20</sub>NO<sub>6</sub>FS: 457.0995; found: 457.0993 [M]<sup>+</sup>; HPLC separation conditions: Chiralcel OD-H, 20 °C, 254 nm, 4:1 hexane:*i*-PrOH, 0.8 mL/min;  $t_R = 31.8$  min (major enantiomer), 50.4 min (minor enantiomer).

#### 4.1.7. 3-(Biphenyl-4-yl)-2-fluoro-4-nitro-1-phenyl-2-(phenylsulfonyl)butan-1-one 5q

White solid; Mp: 125–126 °C;  $[\alpha]_D^{25} = 29.4$  (c = 0.78 in CHCl<sub>3</sub>); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.78 (d, J = 7.9 Hz, 2H), 7.60 (t, J = 7.6 Hz, 1H), 7.48–7.39 (m, 11H), 7.35–7.30 (m, 1H), 7.24 (d, J = 8.6 Hz, 4H), 5.59–5.51 (m, 1H), 5.26–5.20 (m, 1H), 4.83–4.73 (m, 1H); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>)  $\delta$  –146.51 (d, J = 16.2 Hz, 1F); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  193.5 (d, J = 24.1 Hz), 142.1, 139.9, 135.2, 134.4, 134.1, 130.7, 130.5, 130.2, 129.6, 129.5, 129.2, 128.9, 127.8, 127.6, 127.0, 110.4 (d, J = 241.4 Hz), 75.4 (d, J = 4.3 Hz), 47.2 (d, *J* = 22.8 Hz); IR (KBr)  $\nu$  2923, 1677, 1595, 1556, 1448, 1334, 1158 cm<sup>-1</sup>; ESI-MS (*m*/*z*): 526.2 (M + 23)<sup>+</sup>; HRMS (EI): *m*/*z*: calcd. for C<sub>28</sub>H<sub>22</sub>NO<sub>5</sub>FS: 503.1203; found: 503.1099 [M]<sup>+</sup>; HPLC separation conditions: Chiralcel ADH, 20 °C, 254 nm, 4:1 hexane:*i*-PrOH, 0.9 mL/min; *t*<sub>R</sub> = 57.3 min (minor enantiomer), 86.9 min (major enantiomer).

#### 4.1.8. 2-Fluoro-4-nitro-3-(4-nitrophenyl)-1-phenyl-2-(phenylsulfonyl)butan-1-one **5h**

Red oil;  $[\alpha]_D^{28} = 30.4$  (*c* = 1.10 in CHCl<sub>3</sub>); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.09 (AB, *J* = 8.7 Hz, 2H), 7.76 (AB, *J* = 8.7 Hz, 2H), 7.62 (t, *J* = 7.4 Hz, 1H), 7.50–7.37 (m, 7H), 7.23 (t, *J* = 8.4 Hz, 1H), 5.57–5.48 (m, 1H), 5.29–5.17 (m, 1H), 4.99–4.87 (m, 1H); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>)  $\delta$  –1447.68 (d, *J* = 16.1 Hz, 1F); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  192.5 (d, *J* = 23.8 Hz), 148.3, 139.1, 135.6, 134.7, 134.0, 130.7, 129.6, 129.5, 129.4, 128.5, 123.9, 110.3 (d, *J* = 243.4 Hz), 74.9 (d, *J* = 21.4 Hz), 47.0 (d, *J* = 21.5 Hz); IR (film)  $\nu$  3071, 1676, 1596, 1561, 1448, 1349, 1160 cm<sup>-1</sup>; ESI-MS (*m*/*z*): 495.1 (M + 23)<sup>+</sup>; HRMS (ESI): *m*/*z*: calcd. for C<sub>22</sub>H<sub>17</sub>N<sub>2</sub>O<sub>7</sub>FSNa: 495.0633; found: 495.0639 [M + 23]<sup>+</sup>; HPLC separation conditions: Chiralcel ASH, 20 °C, 254 nm, 4:1 hexane:*i*-PrOH, 0.8 mL/min; *t*<sub>R</sub> = 96.8 min (major enantiomer), 129.0 min (minor enantiomer).

#### 4.1.9. 3-(2-Bromophenyl)-2-fluoro-4-nitro-1-phenyl-2-(phenylsulfonyl)butan-1-one 5i

Colorless oil;  $[\alpha]_D^{26} = -51.9$  (c = 1.14 in CHCl<sub>3</sub>); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.04 (d, J = 7.5 Hz, 2H), 7.74 (t, J = 7.6 Hz, 1H), 7.67–7.42 (m, 6H), 7.34–7.25 (m, 2H), 7.14–7.01 (m, 3H), 6.06– 5.85 (m, 1H), 5.35–5.20 (m, 2H); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>)  $\delta$ –146.56 (s, 1F); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  193.8 (d, J = 24.9 Hz), 135.7, 135.6 (d, J = 4.4 Hz), 134.2, 134.1, 133.4, 132.1, 131.2, 130.5, 129.8 (d, J = 8.1 Hz), 129.6, 128.3, 128.2, 128.1, 127.6, 109.4 (d, J = 240.7 Hz), 75.8 (d, J = 5.9 Hz), 45.3 (d, J = 23.5 Hz); IR (film)  $\nu$  3020, 1711, 1561, 1445, 1376, 1216, 756 cm<sup>-1</sup>; ESI-MS (m/z): 528.0 (M + 23)<sup>+</sup>; HRMS (EI): m/z: calcd. for C<sub>22</sub>H<sub>17</sub>NO<sub>5</sub>FSBr: 504.9995; found: 504.9991 [M]<sup>+</sup>; HPLC separation conditions: Chiralcel ADH, 20 °C, 254 nm, 4:1 hexane:*i*-PrOH, 0.8 mL/min;  $t_R = 29.9$  min (minor enantiomer), 44.4 min (major enantiomer).

#### 4.1.10. 3-(3-Bromophenyl)-2-fluoro-4-nitro-1-phenyl-2-(phenylsulfonyl)butan-1-one 5j

Colorless oil;  $[\alpha]_D^{26} = -34.1$  (*c* = 1.03 in CHCl<sub>3</sub>); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.76 (d, *J* = 7.7 Hz, 2H), 7.64 (t, *J* = 7.1 Hz, 1H), 7.51–7.24 (m, 9H), 7.18–7.02 (m, 2H), 5.59–5.43 (m, 1H), 5.25–5.04 (m, 1H), 4.79–4.57 (m, 1H); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>)  $\delta$ –147.68 (s, 1F); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  193.1 (d, *J* = 24.0 Hz), 135.5, 135.1 (d, *J* = 4.2 Hz), 134.3, 134.2, 133.9, 132.9, 132.5, 130.6, 130.5, 129.6 (d, *J* = 14.0 Hz), 129.3, 128.4, 128.3, 123.0, 110.2 (d, *J* = 242.8 Hz), 75.2 (d, *J* = 4.5 Hz), 47.0 (d, *J* = 22.0 Hz); IR (film)  $\nu$ 3020, 1720, 1562, 1446, 1216, 758 cm<sup>-1</sup>; ESI-MS (*m/z*): 528.1 (M + 23)<sup>+</sup>; HRMS (EI): *m/z*: calcd. for C<sub>22</sub>H<sub>17</sub>NO<sub>5</sub>FSBr: 504.9995; found: 505.0000 [M]<sup>+</sup>; HPLC separation conditions: Chiralcel ODH, 20 °C, 254 nm, 4:1 hexane:*i*-PrOH, 0.8 mL/min; *t*<sub>R</sub> = 23.2 min (major enantiomer), 41.0 min (minor enantiomer).

#### 4.1.11. 2-Fluoro-3-(naphthalen-2-yl)-4-nitro-1-phenyl-2-(phenylsulfonyl)butan-1-one 5k

Colorless oil;  $[\alpha]_D^{25} = -52.2$  (*c* = 2.00 in CHCl<sub>3</sub>); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.87–7.78 (m, 4H), 7.73–7.62 (m, 2H), 7.55– 7.45 (m, 4H), 7.39–7.30 (m, 1H), 7.27–7.08 (m, 6H), 5.98 (d, *J* = 14.3 Hz, 1H), 5.78–5.70 (m, 1H), 5.43 (dd, *J* = 2.7, 14.1 Hz, 1H); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>)  $\delta$  –145.30 (d, *J* = 8.3 Hz, 1F); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  194.2 (d, *J* = 25.0 Hz), 135.5, 135.4, 134.0, 133.2, 130.9, 130.0, 129.6, 129.5, 129.4, 128.9, 128.7, 128.2, 127.2, 126.4, 125.4, 124.9, 123.0, 110.1 (d, *J* = 243.4 Hz), 76.2 (d, *J* = 5.3 Hz), 40.2 (d, *J* = 22.9 Hz); IR (film)  $\nu$  3064, 1677, 1596, 1556, 1448, 1336, 1159 cm<sup>-1</sup>; ESI-MS (*m*/*z*): 500.1 (M + 23)<sup>+</sup>; HRMS (EI): *m*/*z*: calcd. for C<sub>26</sub>H<sub>20</sub>NO<sub>5</sub>FS: 477.1046; found: 477.1043 [M]<sup>+</sup>; HPLC separation conditions: Chiralcel ADH, 20 °C, 254 nm, 4:1 hexane:*i*-PrOH, 0.7 mL/min; *t*<sub>R</sub> = 34.4 min (minor enantiomer), 62.4 min (major enantiomer).

#### 4.1.12. 2-Fluoro-3-(furan-2-yl)-4-nitro-1-phenyl-2-(phenylsulfonyl)butan-1-one 51

Red oil;  $[\alpha]_D^{26} = 54.2$  (*c* = 1.40 in CHCl<sub>3</sub>); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.87 (d, *J* = 7.9 Hz, 2H), 7.66 (t, *J* = 7.3 Hz, 1H), 7.57–7.44 (m, 3H), 7.44–7.31 (m, 2H), 7.27–7.18 (m, 3H), 6.33–6.19 (m, 2H), 5.67 (d, *J* = 14.1 Hz, 1H), 5.28–5.08 (m, 1H), 4.89–4.68 (m, 1H); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>)  $\delta$  –144.81 (d, *J* = 7.1 Hz, 1F); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  192.8 (d, *J* = 24.1 Hz), 145.2, 143.7, 135.6, 134.9 (d, *J* = 4.5 Hz), 134.0, 133.9, 130.8, 129.5, 129.4, 129.3, 128.2, 112.0, 111.0, 108.1 (d, *J* = 241.4 Hz), 73.8 (d, *J* = 4.5 Hz), 41.7 (d, *J* = 23.5 Hz); IR (film)  $\nu$  1724, 1679, 1561 cm<sup>-1</sup>; ESI-MS (*m*/*z*): 440.1 (M + 23)<sup>+</sup>; HRMS (EI): *m*/*z*: calcd. for C<sub>20</sub>H<sub>16</sub>NO<sub>6</sub>FS: 417.0682; found: 417.0680 [M]<sup>+</sup>; HPLC separation conditions: Chiralcel ODH, 20 °C, 254 nm, 4:1 hexane:*i*-PrOH, 0.6 mL/min; *t*<sub>R</sub> = 17.7 min (major enantiomer), 37.1 min (minor enantiomer).

# 4.1.13. 2-Fluoro-4-nitro-1-phenyl-2-(phenylsulfonyl)-3-(thiophen-2-yl)butan-1-one 5m

Red oil;  $[\alpha]_{D}^{25} = 35.6$  (*c* = 1.50 in CHCl<sub>3</sub>); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.79 (d, *J* = 8.1 Hz, 2H), 7.63 (t, *J* = 7.2 Hz, 1H), 7.53–7.43 (m, 5H), 7.30–7.14 (m, 3H), 6.96 (d, *J* = 3.2, 1H), 6.89–6.79 (m, 1H), 5.69–5.55 (m, 1H), 5.27–5.15 (m, 1H), 5.10–4.97 (m, 1H); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>)  $\delta$  –144.83 (d, *J* = 18.4 Hz, 1F); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  193.1 (d, *J* = 25.5 Hz), 135.5, 135.1 (d, *J* = 4.3 Hz), 134.2, 133.4, 130.6, 129.6, 129.5, 129.5, 129.4, 128.3, 127.3, 127.2, 109.6 (d, *J* = 242.4 Hz), 76.5 (d, *J* = 4.3 Hz), 43.4 (d, *J* = 22.7 Hz); IR (film)  $\nu$  3066, 1677, 1596, 1561, 1448, 1342, 1160 cm<sup>-1</sup>; ESI-MS (*m*/*z*): 456.1 (M + 23)<sup>+</sup>; HRMS (EI): *m*/*z*: calcd. for C<sub>20</sub>H<sub>16</sub>NO<sub>5</sub>FS<sub>2</sub>: 433.0454; found: 433.0449 [M]<sup>+</sup>; HPLC separation conditions: Chiralcel ODH, 20 °C, 254 nm, 4:1 hexane:*i*-PrOH, 0.6 mL/min; *t*<sub>R</sub> = 21.2 min (major enantiomer), 42.3 min (minor enantiomer).

#### 4.1.14. 2-Fluoro-3-(nitromethyl)-1-phenyl-2-(phenylsulfonyl)heptan-1-one **5n**

Colorless oil;  $[\alpha]_D^{25} = 65.1$  (*c* = 1.30 in CHCl<sub>3</sub>); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.91 (AB, *J* = 7.3 Hz, 2H), 7.78–7.65 (m, 3H), 7.65–7.45 (m, 3H), 7.41–7.26 (m, 2H), 5.64–5.92 (m, 1H), 4.69–4.62 (m, 1H), 3.51–3.22 (m, 1H), 1.94–1.58 (m, 1H), 1.56–1.36 (m, 6H), 0.97–0.68 (m, 3H); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>)  $\delta$  –148.27 (d, *J* = 7.1 Hz, 1F); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  193.1 (d, *J* = 24.2 Hz), 135.4, 135.3, 134.2, 130.1, 129.8, 129.7, 129.3, 128.5, 111.4 (d, *J* = 241.1 Hz), 75.4 (d, *J* = 5.9 Hz), 41.7 (d, *J* = 17.7 Hz), 28.8 (d, *J* = 3.8 Hz), 28.65, 22.5, 13.6; IR (film)  $\nu$  2960, 1678, 1596, 1555, 1448, 1335, 1161 cm<sup>-1</sup>; ESI-MS (*m*/*z*): 430.1 (M + 23)<sup>+</sup>; HRMS (EI): *m*/*z*: calcd. for C<sub>20</sub>H<sub>22</sub>NO<sub>5</sub>FS: 407.1203; found: 407.1192 [M]<sup>+</sup>; HPLC separation conditions: Chiralcel ASH, 20 °C, 254 nm, 4:1 hexane:*i*-PrOH, 0.5 mL/min; *t*<sub>R</sub> = 75.3 min (major enantiomer), 78.7 min (minor enantiomer).

#### 4.1.15. 2-Fluoro-4-methyl-3-(nitromethyl)-1-phenyl-2-(phenylsulfonyl)pentan-1-one **50**

Colorless oil;  $[\alpha]_D^{27} = 85.2$  (*c* = 0.90 in CHCl<sub>3</sub>); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.97 (d, *J* = 7.8 Hz, 2H), 7.84–7.63 (m, 3H), 7.58–7.53 (m, 3H), 7.39–7.34 (m, 2H), 5.69 (d, *J* = 15.5 Hz, 1H), 4.76–4.65 (m, 1H), 3.58–3.44 (m, 1H), 2.32–2.13 (m, 1H), 0.86–0.80 (m, 6H); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>)  $\delta$  –149.81 (d, *J* = 7.2 Hz, 1F); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  193.4 (d, *J* = 25.5 Hz), 135.5, 135.3 (d, *J* = 4.5 Hz) 134.1, 134.0, 131.1, 130.1 (d, *J* = 8.7 Hz), 129.3, 128.4, 111.4 (d, *J* = 241.4 Hz), 72.5 (d, *J* = 6.7 Hz), 46.3 (d, *J* = 21.0 Hz), 28.1 (d, *J* = 3.4 Hz), 20.5, 18.9 (d, *J* = 2.3 Hz); IR (film)  $\nu$  2970, 1677, 1596, 1557, 1469, 1448, 1335, 1160 cm<sup>-1</sup>; ESI-MS (*m*/*z*): 416.1 (M + 23)<sup>+</sup>; HRMS (ESI): *m*/*z*: calcd. for C<sub>19</sub>H<sub>20</sub>NO<sub>5</sub>FSNa: 416.0938; found: 416.0937 [M]<sup>+</sup>; HPLC separation conditions: Chiralcel ODH, 20 °C, 254 nm, 9:1 hexane:*i*-PrOH, 0.7 mL/min; *t*<sub>R</sub> = 12.5 min (major enantiomer), 17.6 min (minor enantiomer).

#### 4.1.16. 4-Fluoro-3,5-diphenyl-4-(phenylsulfonyl)-3,4-dihydro-2Hpyrrole 1-oxide 6

To the solution of **5a** (40 mg, 0.1 mmol) in the mixture of methanol (1 mL) and dichloromethane (1 mL) at room temperature was added palladium on carbon (4 mg, 10% by weight). And the reaction mixture was stirred for 48 h under a balloon  $H_2$  atmosphere and then filtered through celite, which was subsequently washed with dichloromethane three times. The filtrate was concentrated in vacuo and then separated by flash chromatography (ethyl acetate/dichloromathane/petro ether:1/1/3) to provide white solid product **6** 28 mg, in 71% yield.

White solid; Mp: 120 °C.  $[\alpha]_D^{27} = -62.5$  (c = 0.90 in CHCl<sub>3</sub>); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.77 (d, J = 8.0 Hz, 2H), 7.60 (d, J = 8.3 Hz, 2H), 7.48 (t, J = 7.5 Hz, 1H), 7.39–7.30 (m, 3H), 7.17–7.17 (m, 5H), 7.10 (t, J = 7.6 Hz, 1H), 4.93–4.86 (m, 1H), 4.66 (d, J = 8.0 Hz, 1H), 4.41 (d, J = 4.3 Hz, 1H); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>)  $\delta$  –145.45 (d, J = 5.2 Hz, 1F); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  134.8, 134.5 (d, J = 6.5 Hz), 134.1, 130.5, 130.4, 129.2, 128.8, 128.7, 128.4, 128.0, 127.8, 127.7, 126.4, 114.1 (d, J = 238.4 Hz), 69.0, 42.0 (d, J = 19.8 Hz); IR (film)  $\nu$  3064, 1575, 1548, 1495, 1446, 1379, 1326, 1155, 1083 cm<sup>-1</sup>; ESI-MS (m/z): 396.2 (M + 1)<sup>+</sup>, 418.1 (M + 23)<sup>+</sup>; HRMS (EI): m/z: calcd. for C<sub>22</sub>H<sub>18</sub>NO<sub>3</sub>FS: 395.0991; found: 395.0999 [M]<sup>+</sup>; HPLC separation conditions: Chiralcel OD, 20 °C, 254 nm, 4:1 hexane:*i*-PrOH, 0.7 mL/min;  $t_R = 21.6$  min (major enantiomer), 25.7 min (minor enantiomer).

#### Acknowledgements

We are grateful to National Basic Research Program of China (973 Program, 2010CB833300), National Natural Science Foundation of China for financial support (Nos. 21032006, 20172064, 20532040), Shanghai Natural Science Council, and Excellent Young Scholars Foundation of National Natural Science Foundation of China (20525208).

#### Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.jfluchem.2011.05.029.

#### References

- (a) S. Purser, P.R. Moore, S. Swallow, V. Gouverneur, Chem. Soc. Rev. 37 (2008) 320–330;
  - (b) K. Muller, C. Faeh, F. Diederich, Science 317 (2007) 1881-1886;
  - (c) K. Mikami, Y. Itoh, Y.M. Yamamaka, Chem. Rev. 104 (2004) 1-16;
  - (d) B.E. Smart, J. Fluorine Chem. 109 (2001) 3-11.
- [2] (a) Selected examples for the transition metal-based fluorination methods D.S. Reddy, N. Shibata, J. Nagai, S. Nakamura, T. Toru, S. Kanemasa, Angew. Chem. Int. Ed. 47 (2008) 164–168;
- (b) M. Nakamura, A. Hajra, K. Endo, E. Nakamura, Angew. Chem. Int. Ed. 44 (2005) 7248–7251;

(c) N. Shibata, J. Kohno, K. Takai, T. Ishimaru, S. Nakamura, T. Toru, S. Kanemasa, Angew. Chem. Int. Ed. 44 (2005) 4204–4207;

(d) Y. Hamashima, T. Suzuki, H. Takano, Y. Shimura, M. Sodeoka, J. Am. Ceram. Soc. 127 (2005) 10164–10165;

(e) Y. Hamashima, K. Yagi, H. Takano, L. Tamas, M. Sodeoka, J. Am. Ceram. Soc. 124 (2002) 14530–14531;

(f) L. Hintermann, A. Togni, Angew. Chem. Int. Ed. 39 (2000) 4359-4362;

(g) Selected examples for organocatalytic fluorination methods T. Ishimaru, N. Shibata, T. Horikawa, N. Yasuda, S. Nakamura, T. Toru, M. Shiro, Angew. Chem. Int. Ed. 47 (2008) 4157–4161;

(h) S. Brandes, B. Niess, M. Bella, A. Prieto, J. Overgaard, K.A. Jøgensen, Chem. Eur. J. 12 (2006) 6039–6052;

(i) D.Y. Kim, E.J. Park, Org. Lett. 4 (2002) 545-547;

(j) M. Marigo, T.C. Wabnitz, D.K. Fielenbach, A. Jøgensen, Angew. Chem. Int. Ed. 44 (2005) 3703–3706;

(k) D.D. Steiner, N. Mase, C.F. Babars III, Angew. Chem. Int. Ed. 44 (2005) 3706-3710;

- (I) T.D. Beeson, D.W.C. MacMillan, J. Am. Ceram. Soc. 127 (2005) 8826–8828;
   (m) H. Jiang, A. Falcicchio, K.L. Jensen, M.W. Paixão, S. Bertelsen, K.A. Jørgensen,
   J. Am. Ceram. Soc. 131 (2009) 7153–7157.
- [3] (a) For recent reviews, see V.A. Brunet, D. O'Hagan, Angew. Chem. Int. Ed. 47 (2008) 1179–1182;

(b) R. Smits, C.D. Cadicamo, K. Burger, B. Koksch, Chem. Soc. Rev. 37 (2008) 1727-1739;

- (c) G.K.S. Prakash, P. Beier, Angew. Chem. Int. Ed. 45 (2006) 2172-2174;
- (d) P.M. Pihko, Angew. Chem. Int. Ed. 45 (2006) 544-547;
- (e) M. Oestreich, Angew. Chem. Int. Ed. 44 (2005) 2324-2327;
- (f) H. Ibrahim, A. Togni, Chem. Commun. (2004) 1147-1155;
- (g) J.A. Ma, D. Cahard, Chem. Rev 104 (2004) 6119-6146.
- [4] (a) Selected examples for organocatalytic methods using fluorine-containing building blocks S. Mizuta, N. Shibata, Y. Goto, T. Furukawa, S. Nakamura, T. Toru, J. Am. Ceram. Soc. 129 (2007) 6394–6395;

(b) T. Furukawa, N. Shibata, S. Mizuta, S. Nakamura, T. Toru, M. Shiro, Angew. Chem. Int. Ed. 47 (2008) 8051–8054;

(c) X. Han, J. Kwiatkowski, F. Xue, K.W. Huang, Y.X. Lu, Angew. Chem. Int. Ed. 48 (2009) 7604-7607;

(d) Z.Y. Jiang, Y.H. Pan, Y.J. Zhao, T. Ma, R. Lee, Y.Y. Yang, K.W. Huang, M.W. Wang, C.H. Tan, Angew. Chem. Int. Ed. 48 (2009) 3627–3631;

(e) H. Li, S.L. Zhang, C.G. Yu, X.X. Song, W. Wang, Chem. Commun. (2009) 2136-2138:

- (f) X. Han, J. Luo, C. Liu, Y.X. Lu, Chem. Commun. (2009) 2044-2046;
- (g) C.H. Ding, K. Maruoka, Synlett 64 (2009) 664–666;

(h) A. Landa, Á. Puente, J.I. Santos, S. Vera, M. Oiarbide, C. Palomo, Chem. Eur. J. 15 (2009) 11954–11962;

 F. Ullah, G.L. Zhao, L. Deiana, M.Z. Zhu, P. Dziedzic, I. Ibrahem, P. Hammar, J.L. Sun, A. Córdova, Chem. Eur. J. 15 (2009) 10013–10017;

(j) G.K.S. Prakash, F. Wang, T. Stewart, T. Mathew, G.A. Olah, Proc. Natl. Acad. Sci. U.S.A. 106 (2009) 4090-4094;

(k) G.K.S. Prakash, X.M. Zhao, S. Chacko, F. Wang, H. Vaghoo, G.A. Olah, Beilstein. J. Org. Chem. 4 (2008) 17;

- G.F. Zhong, J.H. Fan, C.F. Barbas III, Tetrahedron Lett. 45 (2004) 5681–5684.
   H.F. Cui, Y.Q. Yang, Z. Chai, P. Li, C.W. Zheng, S.Z. Zhu, G. Zhao, J. Org. Chem. 75 (2010) 117–122.
- [6] (a) For recent reviews, see J. Hu, W. Zhang, F. Wang, Chem. Commun. 48 (2009) 7465–7478;

(b) G.K.S. Prakash, J. Hu, Acc. Chem. Res. 40 (2007) 921-930.

- [7] The Nitro Group in Organic Synthesis, John Wiley & Sons, Inc., New York, NY, USA, 2001, 392 pp..
- [8] CCDC-806008 contains the supplementary crystallographic data for 5d. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data\_request/cif.
- [9] (a) H. Feuer, Nitrile Oxides Nitrones and Nitronates in Organic Synthesis: Novel Strategies in Synthesis, 2nd ed., Wiley-Interscience, Hoboken, 2008;
  (b) K.B.G. Torssell, Nitrile Oxides Nitrones and Nitronates in Organic Synthesis: Novel Strategies in Synthesis, VCH, New York, 1988;
- (c) E. Breuer, H. Aurich, Nitrones Nitronates and Nitroxides, Wiley, New York, 1989 [10] (a) For recent reviews, see M. Kissane, A.R. Maguire, Chem. Soc. Rev. 39 (2010)
  - 845-883; (b) A. Brandi, F. Cardona, S. Cicchi, F.M. Cordero, A. Goti, Chem. Eur. J. 15 (2009) 7808-7821;
  - (c) V. Nair, T.D. Suja, Tetrahedron 63 (2007) 12247-12275;
  - (d) H. Pellissier, Tetrahedron 63 (2007) 3235-3285;
  - (e) F. Cardona, A. Goti, Angew. Chem. Int. Ed. 44 (2005) 7832-7835;
  - (f) K.V. Gothelf, K.A. Jørgensen, Chem. Commun. (2000) 1449-1458.